

## PCR-/NAT Carbapenemasen (RV 544) Nov 2020



**Tabelle 1: Probenzusammensetzung und erwartetes Ergebnis.**

*Sample composition and expected results.*

	<i>Erwartet / expected</i>		<i>Probenzusammensetzung / Sample composition</i>
2025441	+++	61 / 72	<i>Serratia marcescens</i> VIM-4 (~ 1x10 <sup>7</sup> genome copies/mL)
2025442	∅	62	<i>Escherichia coli</i> K12
2025443	+++	61 / 73	<i>E. coli</i> OXA-162 (~ 1x10 <sup>7</sup> genome copies/mL)
2025444	+++	61 / 74	<i>C. freundii</i> complex GES-5 (~ 1x10 <sup>7</sup> genome copies/mL)

**Tabelle 2: Häufigkeit der Mitteilung verschiedener Befunde.**

*Absolute numbers of reported individual results.*

<i>n = 80</i>	<i>Probennummer (Sample no.)</i>					<i>Inhibition</i>			
	2025441	2025442	2025443	2025444		2025441	2025442	2025443	2025444
<b>Befund</b> <i>Result</i>									
<b>Positiv</b>	80	1	80	21	n.d.	2	2	2	2
<b>Negativ</b>	0	79	0	58	nein <i>no</i>	78	78	78	78
<b>Fraglich</b> <i>Questionable</i>	0	0	0	1	ja <i>yes</i>	0	0	0	0

**Tabelle 3: Häufigkeit richtig positiver und richtig negativer NAT-Befunde bei Anwendern verschiedener Methoden.**

*Absolute numbers and relative frequency of reported true positive and true negative results among various NAT methods.*

<b>NAT-Methode</b> [Code] (total number *)	<b>NAT richtig positiv</b> <i>True positive results</i>						<b>NAT richtig negativ</b>	
	2025441		2025443		2025444		2025442	
	<i>Absolut</i> <i>Absolute</i>	%	<i>Absolut</i> <i>Absolute</i>	%	<i>Absolut</i> <i>Absolute</i>	%	<i>Absolut</i> <i>Absolute</i>	%
AID Carbapenemase (n = 3)	3	100	3	100	0	0	3	100
Amplex eazyplex SuperBug A/B/C(n=10)	10	100	10	100	6	60	10	100
Cepheid Xpert Carba-R (n = 42)	42	100	42	100	4	10	42	100
Seegene Allplex Entero-DR (n = 5)	5	100	5	100	1	20	4	80
LightMix Modular Carbapenemase (n= 4)	4	100	4	100	2	50	4	100
Other commercial tests (n = 6)	6	100	6	100	0	0	6	100
<i>In house</i> PCR assay (n = 10)	10	100	10	100	8	80	10	100